

PATENT AGENT

Jodi L. Connolly, Ph.D.

jodi.connolly@klarquist.com



EDUCATION

- Ph.D., Department of Microbiology and Immunology, Vanderbilt University, 2001
- B.S. with Honors in Biology, minor in Chemistry, Willamette University, 1996

BAR ADMISSIONS

- U.S. Patent and Trademark Office, 2003 (Reg. No. 54,044)

YEAR JOINED FIRM

2007

PRACTICE AREAS

Patents: International and Utility

TECHNOLOGIES

Life Sciences

PRACTICE AREA OVERVIEW

Dr. Connolly prepares and prosecutes U.S., international, and foreign patent applications. Dr. Connolly also performs prior art searches and assists in the preparation of patentability opinions.

TECHNICAL EXPERTISE

Dr. Connolly's expertise includes many areas of biotechnology, including virology, immunology, vaccines, oncology, monoclonal antibodies, molecular biology, genetics, biochemistry, gene therapy, RNA interference, and antisense technology.

PRIOR PROFESSIONAL EXPERIENCE

Isis Pharmaceuticals, Inc.

Senior Patent Agent | 2003 - 2007

Responsibilities included managing patent portfolios in the field of antisense technology and preparing and prosecuting U.S. and international patent applications.

Fish and Richardson, P.C.

Patent Agent | 2003

Practice emphasized patent prosecution in biotechnology, including gene therapy, molecular biology, biochemistry, virology, immunology, and medical devices.

Heller Ehrman White and McAuliffe, LLP

Scientific Advisor/Patent Agent | 2002 - 2003

Practice emphasized patent prosecution in biotechnology, including gene therapy, molecular biology, biochemistry, virology, immunology, and medical devices.

The Scripps Research Institute

Research Associate | 2001 - 2002

Studies focused on the interaction of adenovirus with cellular factors involved in the host innate immune response in order to better design an adenoviral gene therapy vector.

Vanderbilt University Medical Center

Graduate Student and Postdoctoral Research Fellow | 1996 - 2001

Research focused on elucidating the mechanisms by which double-stranded RNA viruses induce cell death and identifying viral and cellular components that result in viral pathogenesis in host organisms.

PROFESSIONAL ACTIVITIES

- Member, American Intellectual Property Law Association

PATENT AGENT

Jodi L. Connolly, Ph.D.

jodi.connolly@klarquist.com

PRESENTATIONS AND PUBLICATIONS

- S.E. Rodgers, J.L. Connolly, J.D. Chappell, and T.S. Dermody. 1998. Reovirus growth in cell culture does not require the full complement of viral proteins: Identification of a s1s-null mutant. *J. Virol.* 72:8597-8604.
- J.L. Connolly, S.E. Rodgers, P. Clarke, D.W. Ballard, L.D. Kerr, K.L. Tyler, and T.S. Dermody. 2000. Reovirus-induced apoptosis requires activation of transcription factor NF- κ B. *J. Virol.* 74:2981-2989.
- G.J. Poggioli, C.J. Keefer, J.L. Connolly, T.S. Dermody, and K.L. Tyler. 2000. Reovirus-induced G2/M cell cycle arrest requires s1s and occurs in the absence of apoptosis. *J. Virol.* 74:9562-9570.
- E.S. Barton, J.L. Connolly, J.C. Forrest, and T.S. Dermody. 2001. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multi-step adhesion strengthening. *J. Biol. Chem.* 276:2200-2211.
- E.S. Barton, J.C. Forrest, J.L. Connolly, J.D. Chappell, F.J. Schnell, A. Nusrat, C.A. Parkos, and T.S. Dermody. 2001. Identification of junction adhesion molecule as a reovirus receptor. *Cell* 104:441-451.
- J.L. Connolly, E.S. Barton, and T.S. Dermody. 2001. Reovirus binding to cell-surface sialic acid potentiates virus-induced apoptosis. *J. Virol.* 75:4029-4039.
- E.S. Barton, J.D. Chappell, J.L. Connolly, J.C. Forrest, and T.S. Dermody. 2001. Reovirus receptors and apoptosis. *Virology* 190:173-180.
- J.L. Connolly and T.S. Dermody. 2002. Virion Disassembly is Required for Reovirus-Induced Apoptosis. *J. Virol.* 76:1632-1641.
- M. Filippova, H. Song, J.L. Connolly, Terence S. Dermody, and P.J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to TNF R1 and protects cells from TNF-induced apoptosis. *J. Biol. Chem.* 277:21730-21739
- E.S. Barton, B.E. Youree, D.H. Ebert, J.C. Forrest, J.L. Connolly, T. Valyi-Nagy, K. Washington, J.D. Wetzel, and T.S. Dermody. 2003. Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease. *J. Clin. Invest.* 111:1823-1833
- S.M. O'Donnell, M.W. Hansberger, J.L. Connolly, J.D. Chappell, M.J. Watson, J.M. Pierce, J.D. Wetzel, W. Han, E.S. Barton, J.C. Forrest, T. Valyi-Nagy, F.E. Yull, T.S. Blackwell, J.N. Rottman, B. Sherry and T.S. Dermody. 2005. Organ-specific roles for transcription factor NF- κ B in reovirus-induced apoptosis and disease. *J. Clin. Invest.* 115:2341-2350
- M. Iacobelli-Martinez, R.R. Nepomuceno, J. Connolly, G.R. Nemerow. CD46-utilizing adenoviruses inhibit C/EBP β -dependent expression of proinflammatory cytokines, 2005 *J. Virol.* 79:11259-68.

PATENT AGENT

Jodi L. Connolly, Ph.D.

jodi.connolly@klarquist.com

REPRESENTATIVE PATENTS

- Anti-fXI antibodies and methods of use (8,388,959)
- Engineered antibody constant domain molecules (8,580,927)
- Rabies virus-based recombinant immunocontraceptive compositions and methods of use (8,524,247)
- Methods for modulating embryonic stem cell differentiation (8,617,813)
- Recombinant Rift Valley fever (RVF) viruses and methods of use (8,673,629)
- Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome (8,785,414)
- Tolerizing agents (7,910,113)
- Th1-associated microRNAs and their use for tumor immunotherapy (8,486,911)
- Tetravalent influenza vaccine and use thereof (8,513,006)
- Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes (8,551,536)